This company has been acquired
NVCN Stock Overview
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Neovasc Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$30.03 |
| 52 Week High | CA$30.07 |
| 52 Week Low | CA$4.59 |
| Beta | 1.98 |
| 1 Month Change | 2.49% |
| 3 Month Change | 39.42% |
| 1 Year Change | 212.49% |
| 3 Year Change | -54.33% |
| 5 Year Change | -97.50% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Neovasc GAAP EPS of -$3.29 misses by $0.93, revenue of $0.82M beats by $0.13M
Aug 11Neovasc expands direct sales operations to include the UK
Jul 05Neovasc EPS beats by $0.05, misses on revenue
May 06Neovasc receives Nasdaq notification regarding minimum market value deficiency
Dec 11Neovasc plunges in early trade on $6.1M registered direct offering
Dec 08FDA Ad Com thumbs down on Neovasc Reducer; shares plummet 36%
Oct 28Shareholder Returns
| NVCN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.7% | -4.1% | -3.7% |
| 1Y | 212.5% | -2.2% | 20.5% |
Return vs Industry: NVCN exceeded the US Medical Equipment industry which returned -12.1% over the past year.
Return vs Market: NVCN exceeded the US Market which returned -10.3% over the past year.
Price Volatility
| NVCN volatility | |
|---|---|
| NVCN Average Weekly Movement | 8.7% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVCN's share price has been volatile over the past 3 months.
Volatility Over Time: NVCN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 60 | Fred Colen | neovasc.com |
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008.
Neovasc Inc. Fundamentals Summary
| NVCN fundamental statistics | |
|---|---|
| Market cap | US$82.41m |
| Earnings (TTM) | -US$41.20m |
| Revenue (TTM) | US$3.81m |
21.7x
P/S Ratio-2.0x
P/E RatioIs NVCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCN income statement (TTM) | |
|---|---|
| Revenue | US$3.81m |
| Cost of Revenue | US$5.07m |
| Gross Profit | -US$1.27m |
| Other Expenses | US$39.93m |
| Earnings | -US$41.20m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.93 |
| Gross Margin | -33.37% |
| Net Profit Margin | -1,082.90% |
| Debt/Equity Ratio | 79.8% |
How did NVCN perform over the long term?
See historical performance and comparison